OctoPlus' drug Locteron for chronic hepatitis C displayed an antiviral effect in a Phase IIa trial, the Dutch biotech firm said in a statement. OctoPlus, with its partner Biolex Therapeutics, hopes to market Locteron as a treatment that offers a more convenient dosing schedule and fewer side effects than current treatments.

Full Story:

Related Summaries